EE200000471A - N-hüdroksü-2-(alküül-, arüül- või heteroarüülsulfanüül, -sulfinüül või -sulfonüül)-3-asendatud alküül-, arüül- või heteroarüülamiidid maatriksmetalloproteinaasi inhibiitoritena, meetod MMP ja TACE ensüümide toime pärssimiseks ning farmatseutiline kom - Google Patents

N-hüdroksü-2-(alküül-, arüül- või heteroarüülsulfanüül, -sulfinüül või -sulfonüül)-3-asendatud alküül-, arüül- või heteroarüülamiidid maatriksmetalloproteinaasi inhibiitoritena, meetod MMP ja TACE ensüümide toime pärssimiseks ning farmatseutiline kom

Info

Publication number: EE200000471A
Authority: EE; Estonia
Prior art keywords: aryl; alkyl; heteroarylsulfanyl; mmp; sulfinyl
Prior art date: 1998-02-19

Application number

EEP200000471A

Other languages

English (en)

Estonian (et)

Inventor

Mudumbai Venkatesan Aranapakam

Theodore Grosu George

Marie Davis Jamie

Lea Baker Jannie

Ian Levin Jeremy

Original Assignee

American Cyanamid Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-19

Filing date

1998-08-26

Publication date

2002-02-15

1998-08-26 Application filed by American Cyanamid Company filed Critical American Cyanamid Company

2002-02-15 Publication of EE200000471A publication Critical patent/EE200000471A/xx

Links

125000003118 aryl group Chemical group 0.000 title 2
101000777461 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 17 Proteins 0.000 title 1
102000002274 Matrix Metalloproteinases Human genes 0.000 title 1
108010000684 Matrix Metalloproteinases Proteins 0.000 title 1
125000000217 alkyl group Chemical group 0.000 title 1
-1 heteroaryl amides Chemical class 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 title 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/14—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Dermatology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)

EEP200000471A 1998-02-19 1998-08-26 N-hüdroksü-2-(alküül-, arüül- või heteroarüülsulfanüül, -sulfinüül või -sulfonüül)-3-asendatud alküül-, arüül- või heteroarüülamiidid maatriksmetalloproteinaasi inhibiitoritena, meetod MMP ja TACE ensüümide toime pärssimiseks ning farmatseutiline kom EE200000471A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2637298A	1998-02-19	1998-02-19
PCT/US1998/017633 WO1999042436A1 (en)	1998-02-19	1998-08-26	N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Publications (1)

Publication Number	Publication Date
EE200000471A true EE200000471A (et)	2002-02-15

Family

ID=21831431

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200000471A EE200000471A (et)	1998-02-19	1998-08-26	N-hüdroksü-2-(alküül-, arüül- või heteroarüülsulfanüül, -sulfinüül või -sulfonüül)-3-asendatud alküül-, arüül- või heteroarüülamiidid maatriksmetalloproteinaasi inhibiitoritena, meetod MMP ja TACE ensüümide toime pärssimiseks ning farmatseutiline kom

Country Status (21)

Country	Link
EP (1)	EP1054858A1 (no)
JP (1)	JP2002503717A (no)
KR (1)	KR20010041089A (no)
CN (1)	CN1213021C (no)
AU (1)	AU757719B2 (no)
BG (1)	BG104782A (no)
BR (1)	BR9815781A (no)
CA (1)	CA2320469A1 (no)
EA (1)	EA003283B1 (no)
EE (1)	EE200000471A (no)
GE (1)	GEP20022797B (no)
HR (1)	HRP20000543A2 (no)
HU (1)	HUP0101837A3 (no)
ID (1)	ID25639A (no)
IL (1)	IL137566A0 (no)
NO (1)	NO20004093L (no)
NZ (1)	NZ506184A (no)
PL (1)	PL342548A1 (no)
SK (1)	SK12332000A3 (no)
TR (1)	TR200002423T2 (no)
WO (1)	WO1999042436A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001523662A (ja)	1997-11-14	2001-11-27	ジー・ディー・サール・アンド・カンパニー	芳香族スルホンヒドロキサム酸メタロプロテアーゼ阻害剤
US6750228B1 (en)	1997-11-14	2004-06-15	Pharmacia Corporation	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) *	1997-11-14	2001-11-08	Thomas E Barta	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
AR035312A1 (es) *	1999-01-27	2004-05-12	Wyeth Corp	Compuestos de acido hidroxamico que contienen alquinilo como inhibidores de metaloproteinasa de matriz/tace, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento
US6358980B1 (en) *	1999-01-27	2002-03-19	American Cyanamid Company	Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6800646B1 (en)	1999-02-08	2004-10-05	Pharmacia Corporation	Sulfamato hydroxamic acid metalloprotease inhibitor
GEP20043238B (en)	1999-02-08	2004-05-25	Searle & Co	Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity
WO2001055112A1 (en) *	2000-01-27	2001-08-02	American Cyanamid Company	Method for preparing alpha-sulfonyl hydroxamic acid derivatives
AR028537A1 (es) *	2000-04-14	2003-05-14	Abbott Lab	Hidrazidas y alcoxiamidas inhibidoras de la angiogénesis
US20020002152A1 (en)	2000-04-14	2002-01-03	Craig Richard A.	Hydrazide and alkoxyamide angiogenesis inhibitors
US6683093B2 (en)	2000-05-12	2004-01-27	Pharmacia Corporation	Aromatic sulfone hydroxamic acids and their use as protease inhibitors
HUP0304069A2 (hu)	2001-05-11	2004-04-28	Pharmacia Corp.	Aromás szulfon-hidroxamátok és proteázgátlókként való alkalmazásuk
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
CA2483314A1 (en)	2002-04-25	2003-11-06	Pharmacia Corporation	Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
CA2490646A1 (en) *	2002-06-25	2003-12-31	Pharmacia Corporation	Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors
TW200418825A (en)	2002-12-16	2004-10-01	Hoffmann La Roche	Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
US20090005344A1 (en) *	2004-11-01	2009-01-01	Nkuada, Llc	Compounds and Methods of Use Thereof
FR2917427B1 (fr) *	2007-06-18	2009-08-21	Galderma Res & Dev	Inhibiteurs de tace dans le traitement de l'acne
FR2947268B1 (fr)	2009-06-30	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
CA2917604C (en) *	2012-07-18	2021-08-10	Josune Orbe Lopategui	New antifibrinolytic compounds
KR101641023B1 (ko) *	2014-08-27	2016-07-20	씨제이헬스케어 주식회사	신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
WO2016032120A1 (ko) *	2014-08-27	2016-03-03	씨제이헬스케어 주식회사	신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
CN107188837B (zh) *	2017-06-06	2019-05-28	温州大学	一种α-酰基高烯丙基硫醚类化合物的合成方法
US12491186B2 (en)	2018-10-04	2025-12-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	EGFR inhibitors for treating keratodermas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8827305D0 (en) *	1988-11-23	1988-12-29	British Bio Technology	Compounds
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) *	1993-01-06	1996-04-09	Ciba-Geigy Corporation	Arylsufonamido-substituted hydroxamic acids
DK0740655T3 (da) *	1994-01-22	2000-03-27	British Biotech Pharm	Metalloproteinaseinhibitorer
PT766664E (pt) *	1994-06-22	2000-08-31	British Biotech Pharm	Inibidores de metaloproteinases
UA58543C2 (uk) *	1997-02-27	2003-08-15	Амерікан Ціанамід Компані	N-гідрокси-2-(алкіл-, арил-, або гетероарилсульфаніл, -сульфініл або -сульфоніл)-3-заміщені алкіл-, арил- або гетероариламіди як інгібітори матричних металопротеїназ
JPH11199512A (ja) *	1997-10-24	1999-07-27	Pfizer Prod Inc	変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
JP2001523662A (ja) *	1997-11-14	2001-11-27	ジー・ディー・サール・アンド・カンパニー	芳香族スルホンヒドロキサム酸メタロプロテアーゼ阻害剤

1998
- 1998-08-26 EA EA200000849A patent/EA003283B1/ru not_active IP Right Cessation
- 1998-08-26 CN CNB988139669A patent/CN1213021C/zh not_active Expired - Fee Related
- 1998-08-26 EE EEP200000471A patent/EE200000471A/xx unknown
- 1998-08-26 GE GEAP19985554A patent/GEP20022797B/en unknown
- 1998-08-26 KR KR1020007009128A patent/KR20010041089A/ko not_active Withdrawn
- 1998-08-26 BR BR9815781-7A patent/BR9815781A/pt not_active Application Discontinuation
- 1998-08-26 HU HU0101837A patent/HUP0101837A3/hu unknown
- 1998-08-26 AU AU91201/98A patent/AU757719B2/en not_active Ceased
- 1998-08-26 CA CA002320469A patent/CA2320469A1/en not_active Abandoned
- 1998-08-26 TR TR2000/02423T patent/TR200002423T2/xx unknown
- 1998-08-26 WO PCT/US1998/017633 patent/WO1999042436A1/en not_active Ceased
- 1998-08-26 HR HR20000543A patent/HRP20000543A2/hr not_active Application Discontinuation
- 1998-08-26 PL PL98342548A patent/PL342548A1/xx unknown
- 1998-08-26 JP JP2000532389A patent/JP2002503717A/ja active Pending
- 1998-08-26 EP EP98943392A patent/EP1054858A1/en not_active Withdrawn
- 1998-08-26 SK SK1233-2000A patent/SK12332000A3/sk unknown
- 1998-08-26 NZ NZ506184A patent/NZ506184A/en unknown
- 1998-08-26 ID IDW20001549A patent/ID25639A/id unknown
- 1998-08-26 IL IL13756698A patent/IL137566A0/xx unknown
2000
- 2000-08-16 NO NO20004093A patent/NO20004093L/no unknown
- 2000-09-19 BG BG104782A patent/BG104782A/bg unknown

Also Published As

Publication number	Publication date
CA2320469A1 (en)	1999-08-26
HUP0101837A3 (en)	2001-11-28
PL342548A1 (en)	2001-06-18
JP2002503717A (ja)	2002-02-05
KR20010041089A (ko)	2001-05-15
EP1054858A1 (en)	2000-11-29
ID25639A (id)	2000-10-19
IL137566A0 (en)	2001-07-24
AU757719B2 (en)	2003-03-06
BG104782A (bg)	2001-08-31
EA003283B1 (ru)	2003-04-24
TR200002423T2 (tr)	2001-01-22
GEP20022797B (en)	2002-09-25
HRP20000543A2 (en)	2001-08-31
NO20004093L (no)	2000-10-03
SK12332000A3 (sk)	2001-02-12
WO1999042436A1 (en)	1999-08-26
NZ506184A (en)	2003-05-30
BR9815781A (pt)	2000-11-07
CN1291183A (zh)	2001-04-11
CN1213021C (zh)	2005-08-03
HUP0101837A2 (hu)	2001-10-28
NO20004093D0 (no)	2000-08-16
AU9120198A (en)	1999-09-06
EA200000849A1 (ru)	2001-04-23

Publication	Publication Date	Title
EE200000471A (et)	2002-02-15	N-hüdroksü-2-(alküül-, arüül- või heteroarüülsulfanüül, -sulfinüül või -sulfonüül)-3-asendatud alküül-, arüül- või heteroarüülamiidid maatriksmetalloproteinaasi inhibiitoritena, meetod MMP ja TACE ensüümide toime pärssimiseks ning farmatseutiline kom
IL131258A0 (en)	2001-01-28	N-hydroxy-2-(alkyl aryl or heteroaryl sulfanyl sulfinyl or sulfonyl)-3-substituted alkyl aryl or heteroarylamides as matrix metalloproteinase inhibitors
IS5739A (is)	2000-11-28	Efnasambönd óstöðugra DP IV-lata
DK1100797T3 (da)	2003-04-22	Heterocycliske forbindelser som inhibitorer af rotamaseenzymer
ID27840A (id)	2001-04-26	Turunan-turunan asam hidroksi pipekolat hidroksamat sebagai inhibitor-inhibitor mmp
DK1060178T3 (da)	2003-11-24	Heterocyklisk forbindelser som inhibitorer af rotamase enzymer
EE200100475A (et)	2002-12-16	Gaaside desulfureerimise meetod
GB9919776D0 (en)	1999-10-27	Compoujnds
ATE227264T1 (de)	2002-11-15	Metalloproteinase-inhibitoren
PT1086076E (pt)	2005-05-31	Inibidores de sulfonamida de aspartil protease
FI954351A7 (fi)	1995-09-15	Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina
ID26822A (id)	2001-02-15	Inhibitor tiol tertentu dari enzim pengubah endotelin
DE60012303D1 (de)	2004-08-26	Alkinylische hydroxamsäureverbindungen als tace inhibitoren
DK0690133T3 (da)	2002-02-04	Fremgangsmåde til enzymatisk spaltning af 2-amino-4-methylphosphinobutansyreamid-derivater
NO20013673D0 (no)	2001-07-26	Acetyleniske bicykliske orto-sulfonamido -og fosfinsyreamidoheteroarylhydroksamsyrer som TACE-inhibitorer
NO20005097L (no)	2000-11-07	Dispersjoner som inneholder homopolymerer eller kopolymerer av hydroksykarboksylsyrer som et reologisk additiv
HK1029113A (en)	2001-03-23	N-hydroxy-2-(alkyl, aryl, of heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
NO20010400D0 (no)	2001-01-23	Isokinoliner som urokinaseinhibitorer
SI0973512T1 (en)	2004-08-31	N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
AU4275000A (en)	2001-03-05	Method for dehumidifying and for reducing destructive salts of brickwork
DK1147102T3 (da)	2004-06-01	Heteroaryl-acetyleniske sulfonamid- og phosphinsyreamid-hydroxamsyre-TACE-inhibitorer
ZA995455B (en)	2001-02-26	N-hydroxy-2(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors.